Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size
| Autor: | Josep-Maria Ribera, Camino Estivill, J. Nomdedeu, José-María Moraleda, Maite Carricondo, Salut Brunet, Montserrat Hoyos, Jordi Sierra, Carmen Martinez, Alicia Domingo, Mar Tormo, J. Bargay, Anna Aventin, Jordi Juncà, Andreu Llorente, Elena Bussaglia, Lourdes Florensa, David Gallardo, Ramon Guardia, Jordi Esteve, M. Gallart, Neus Villamor, M. Mascaró, M.P. Queipo |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Genes Wilms Tumor Myeloid CD33 Kaplan-Meier Estimate Biology Stem cell marker Immunophenotyping Young Adult Antigens CD CEBPA medicine Humans Flow cytometry Aged Acute leukemias Reverse Transcriptase Polymerase Chain Reaction CD117 Nuclear Proteins Myeloid leukemia Histone-Lysine N-Methyltransferase Hematology Middle Aged Flow Cytometry Prognosis medicine.disease Leukemia Myeloid Acute Leukemia medicine.anatomical_structure fms-Like Tyrosine Kinase 3 NPM mutations Oncology Mutation CCAAT-Enhancer-Binding Proteins Cancer research biology.protein Female Nucleophosmin Immunophenotype Myeloid-Lymphoid Leukemia Protein |
| Zdroj: | LEUKEMIA RESEARCH r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2010.05.015 |
| Popis: | NPM mutations are the most common genetic abnormalities found in non-promyelocytic AML. NPM-positive patients usually show a normal karyotype, a peculiar morphologic appearance with frequent monocytic traits and good prognosis in the absence of an associated FLT3 mutation. This report describes the immunophenotypic and genetic characteristics of a consecutive series of NPM-mutated de novo AML patients enroled in the CETLAM trial. Eighty-three patients were included in the study. Complete immunophenotype was obtained using multiparametric flow cytometry. Associated genetic lesions (FLT3, MLL, CEBPA and WT1 mutations) were studied by standardized methods. Real-time PCR was employed to assess the minimal residual status. The most common pattern was CD34-CD15+ and HLA-DR+. Small CD34 populations with immunophenotypic aberrations (CD15 and CD19 coexpression, abnormal SSC) were detected even in CD34 negative samples. Nearly all cases expressed CD33 (strong positivity), CD13 and CD117, and all were CD123+. The stem cell marker CD110 was also positive in most cases. Biologic parameters such as a high percentage of intermediate CD45+ (blast gate) (> 75% nucleated cells), CD123+ and FLT3-ITD mutations were associated with a poor outcome. Quantitative PCR positivity had no prognostic impact either after induction or at the end of chemotherapy. Only PCR positivity (greater than 10 copies) detected in patients in haematological remission was associated with an increased relapse rate. Further studies are required to determine whether the degree of leukemic stem cell expansion (CD45 + CD123 + cells) increases the risk of acquisition of FLT3-ITD and/or provides selective advantages. (C) 2010 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect